Dupont Capital Management Corp reduced its holdings in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 57.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 26,710 shares of the medical research company’s stock after selling 36,306 shares during the period. Dupont Capital Management Corp owned about 0.06% of Enzo Biochem worth $280,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Evermore Global Advisors LLC increased its holdings in Enzo Biochem by 7.3% during the 2nd quarter. Evermore Global Advisors LLC now owns 3,555,233 shares of the medical research company’s stock worth $39,250,000 after purchasing an additional 242,441 shares during the period. Renaissance Technologies LLC increased its holdings in Enzo Biochem by 1.3% during the 2nd quarter. Renaissance Technologies LLC now owns 2,069,600 shares of the medical research company’s stock worth $22,848,000 after purchasing an additional 27,200 shares during the period. Dimensional Fund Advisors LP increased its holdings in Enzo Biochem by 10.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,026,647 shares of the medical research company’s stock worth $22,376,000 after purchasing an additional 193,246 shares during the period. Vanguard Group Inc. increased its holdings in Enzo Biochem by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,752,680 shares of the medical research company’s stock worth $19,350,000 after purchasing an additional 86,922 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC increased its holdings in Enzo Biochem by 20.3% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 999,961 shares of the medical research company’s stock worth $11,040,000 after purchasing an additional 168,607 shares during the period. 62.46% of the stock is owned by hedge funds and other institutional investors.

ENZ has been the topic of several research reports. TheStreet downgraded Enzo Biochem from a “b” rating to a “c+” rating in a report on Wednesday, September 27th. Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, BidaskClub downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th.

Enzo Biochem, Inc. (ENZ) opened at $9.05 on Tuesday. Enzo Biochem, Inc. has a fifty-two week low of $6.27 and a fifty-two week high of $12.04.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/11/14/enzo-biochem-inc-enz-shares-sold-by-dupont-capital-management-corp.html.

In other news, CFO Barry W. Weiner sold 54,126 shares of Enzo Biochem stock in a transaction on Wednesday, October 25th. The stock was sold at an average price of $10.11, for a total value of $547,213.86. Following the transaction, the chief financial officer now directly owns 1,423,367 shares in the company, valued at approximately $14,390,240.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP James Michael O’brien sold 22,866 shares of Enzo Biochem stock in a transaction on Friday, October 27th. The shares were sold at an average price of $10.28, for a total value of $235,062.48. Following the completion of the transaction, the executive vice president now owns 34,886 shares in the company, valued at $358,628.08. The disclosure for this sale can be found here. Insiders sold a total of 191,398 shares of company stock worth $1,925,292 over the last quarter. Company insiders own 9.50% of the company’s stock.

Enzo Biochem Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.